Gastro-oesophageal reflux: clinical profiles and outcome

J Paediatr Child Health. 1999 Dec;35(6):568-71. doi: 10.1046/j.1440-1754.1999.00442.x.

Abstract

Objectives: To assess the clinical features, investigations and outcome of 69 children (40 males, 29 females) with gastro-oesophageal reflux (GOER) referred to a tertiary referral centre in paediatric gastroenterology.

Methods: A study of all patients with significant GOER seen at the Paediatric Gastroenterology Unit, Queen Elizabeth Hospital for Children, Hackney Road, London, between December 1994 and August 1995.

Results: The median age at referral was 16 months. Presenting symptoms were recurrent vomiting (72%), epigastric and abdominal pain (36%), feeding difficulties (29%), failure to thrive (28%) and irritability (19%). Continuous 24-h lower oesophageal pH studies performed in 57 children showed 20 (35%) had a reflux index of between 10% to 20%, 14 (25%) had a index > 20%, and six (11%) had a postprandial reflux index > 10%. Reflux was shown in 38 (62%) of 62 children who underwent barium studies. None had significant anatomical abnormalities, but in the 22 children who had a negative barium studies, six had severe reflux (reflux index > 20%). Upper gastrointestinal endoscopy performed in 47 children showed reflux oesophagitis in 29 (62%), oesophageal ulceration in three, and Barrett's oesophagus in one. All of the children were treated with standard medical therapy. Sixty-six per cent were able to discontinue medication within 12 months and remained well. Four children (6%) required Nissen's fundoplication for failure to respond to medical therapy.

Conclusions: Most infants with GOER have an uncomplicated course. False negative results were noted in both pH monitoring and barium meal. Up to 80% of children, with therapy, will improve within 12 months.

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Cisapride / therapeutic use
  • Esophagoscopy
  • Female
  • Fundoplication
  • Gastroesophageal Reflux / drug therapy*
  • Gastroesophageal Reflux / physiopathology*
  • Gastroesophageal Reflux / surgery
  • Gastrointestinal Agents / therapeutic use
  • Histamine H2 Antagonists / therapeutic use
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Omeprazole / therapeutic use
  • Treatment Outcome

Substances

  • Gastrointestinal Agents
  • Histamine H2 Antagonists
  • Omeprazole
  • Cisapride